Xavier Thomas
Overview
Explore the profile of Xavier Thomas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
288
Citations
7458
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thomas X
Expert Opin Pharmacother
. 2025 Feb;
:1-9.
PMID: 39989126
Introduction: The aim of treatment in very low-, low- and intermediate-1-risk myelodysplastic syndrome (MDS) is mainly to relieve symptoms due to cytopenias. Only a few therapeutic drugs are currently available,...
2.
Cluzeau T, Guolo F, Chiche E, Minetto P, Rahme R, Bertoli S, et al.
Blood Adv
. 2024 Oct;
9(4):752-758.
PMID: 39454204
CPX-351 has been approved for patients with therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (MRC-AML). No extensive data are available on measurable residual disease (MRD) and long-term...
3.
Hirsch P, Lambert J, Bucci M, Deswarte C, Boudry A, Lambert J, et al.
Blood Cancer J
. 2024 Jun;
14(1):97.
PMID: 38871702
The evaluation of measurable residual disease (MRD) in acute myeloid leukemia (AML) using comprehensive mutation analysis by next-generation sequencing (NGS) has been investigated in several studies. However controversial results exist...
4.
Cannas G, Elhamri M, Thomas X
Oncol Ther
. 2024 Mar;
12(2):233-238.
PMID: 38553614
Sickle cell disease (SCD) is a severe monogenic hereditary hemoglobinopathy that is characterized by repeated clinical and biological manifestations able to generate stress erythopoiesis. A clonal hematopoiesis involving mainly variants...
5.
Chalandon Y, Rousselot P, Chevret S, Cayuela J, Kim R, Huguet F, et al.
Blood
. 2024 Mar;
143(23):2363-2372.
PMID: 38452207
We previously demonstrated that a reduced-intensity chemotherapy schedule can safely replace hyper-CVAD (cyclophosphamide-vincristine-doxorubicin [Adriamycin]-dexamethasone) cycle 1 when combined with imatinib in adults with Philadelphia-positive acute lymphoblastic leukemia. In the present...
6.
Thomas X
Oncol Ther
. 2024 Feb;
12(1):57-72.
PMID: 38300432
Recent advances have included insights into the clinical value of genomic abnormalities in acute myeloid leukemia (AML) and consequently the development of numerous targeted therapeutic agents that have improved clinical...
7.
Gabellier L, Peterlin P, Thepot S, Hicheri Y, Paul F, Gallego-Hernanz M, et al.
Ann Hematol
. 2024 Jan;
103(3):759-769.
PMID: 38273140
Very few data are available about hypomethylating agent (HMA) efficiency in core binding factor acute myeloid leukemias (CBF-AML). Our main objective was to evaluate the efficacy and safety of HMA...
8.
Roboz G, Sanz G, Griffiths E, Yee K, Kantarjian H, Recher C, et al.
Blood Adv
. 2024 Jan;
8(8):2020-2029.
PMID: 38231126
Guadecitabine is a novel hypomethylating agent (HMA) resistant to deamination by cytidine deaminase. Patients with relapsed/refractory acute myeloid leukemia (AML) were randomly assigned to guadecitabine or a preselected treatment choice...
9.
Sierra J, Montesinos P, Thomas X, Griskevicius L, Cluzeau T, Caillot D, et al.
Blood Adv
. 2023 Aug;
7(21):6441-6450.
PMID: 37581981
The pivotal RATIFY study demonstrated midostaurin (50 mg twice daily) with standard chemotherapy significantly reduced mortality in adult patients (<60 years) with newly diagnosed (ND) FLT3mut acute myeloid leukemia (AML)....
10.
Fenaux P, Gobbi M, Kropf P, Issa J, Roboz G, Mayer J, et al.
Blood Adv
. 2023 Jun;
7(17):5027-5037.
PMID: 37276510
This phase 3 study evaluated the efficacy and safety of the new hypomethylating agent guadecitabine (n = 408) vs a preselected treatment choice (TC; n = 407) of azacitidine, decitabine,...